55 related articles for article (PubMed ID: 24486518)
1. ⁹⁹mTc carbonyl DTPA-rituximab: preparation and preliminary bioevaluation.
Pandey U; Kameswaran M; Dev Sarma H; Samuel G
Appl Radiat Isot; 2014 Apr; 86():52-6. PubMed ID: 24486518
[TBL] [Abstract][Full Text] [Related]
2. Preparation of (99m)Tc carbonyl DTPA-bevacizumab and its bioevaluation in a melanoma model.
Kameswaran M; Pandey U; Sarma HD; Samuel G
Ann Nucl Med; 2014 Nov; 28(9):911-6. PubMed ID: 25038907
[TBL] [Abstract][Full Text] [Related]
3. Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology.
Dias CR; Jeger S; Osso JA; Müller C; De Pasquale C; Hohn A; Waibel R; Schibli R
Nucl Med Biol; 2011 Jan; 38(1):19-28. PubMed ID: 21220126
[TBL] [Abstract][Full Text] [Related]
4. Preliminary evaluation of the potential of 99mTc carbonyl-DTPA-Rituximab as a tracer for sentinel lymph node detection.
Kameswaran M; Subramanian S; Pandey U; Samuel G
Appl Radiat Isot; 2016 Jan; 107():195-198. PubMed ID: 26524405
[TBL] [Abstract][Full Text] [Related]
5. (99m)Tc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent.
Stopar TG; Mlinaric-Rascan I; Fettich J; Hojker S; Mather SJ
Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):53-9. PubMed ID: 16172899
[TBL] [Abstract][Full Text] [Related]
6. (99m)Tc(CO)(3)-Ibritumomab tiuxetan; a novel radioimmunoimaging (RII) agent of B cell non-Hodgkin's lymphoma (NHL).
Shah SQ; Khan AU; Khan MR
Biol Chem; 2012 Jan; 393(1-2):71-5. PubMed ID: 22628300
[TBL] [Abstract][Full Text] [Related]
7. 99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience.
Gmeiner Stopar T; Fettich J; Zver S; Mlinaric-Rascan I; Hojker S; Socan A; Peitl PK; Mather S
Nucl Med Commun; 2008 Dec; 29(12):1059-65. PubMed ID: 18987526
[TBL] [Abstract][Full Text] [Related]
8. Necrosis avidity of (99m)Tc(CO)3-labeled pamoic acid derivatives: synthesis and preliminary biological evaluation in animal models of necrosis.
Fonge H; Chitneni SK; Lixin J; Vunckx K; Prinsen K; Nuyts J; Mortelmans L; Bormans G; Ni Y; Verbruggen A
Bioconjug Chem; 2007; 18(6):1924-34. PubMed ID: 17929883
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Preclinical Evaluation of (177)Lu-CHX-A"-DTPA-Rituximab as a Radioimmunotherapeutic Agent for Non-Hodgkin's Lymphoma.
Kameswaran M; Pandey U; Dhakan C; Pathak K; Gota V; Vimalnath KV; Dash A; Samuel G
Cancer Biother Radiopharm; 2015 Aug; 30(6):240-6. PubMed ID: 26066665
[TBL] [Abstract][Full Text] [Related]
10. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
Kameswaran M; Pandey U; Dash A; Samuel G; Venkatesh M
Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
[TBL] [Abstract][Full Text] [Related]
11. Design, preparation, in vitro and in vivo evaluation of (99m)Tc-N2S2-Tat(49-57)-bombesin: a target-specific hybrid radiopharmaceutical.
Santos-Cuevas CL; Ferro-Flores G; Arteaga de Murphy C; Ramírez Fde M; Luna-Gutiérrez MA; Pedraza-López M; García-Becerra R; Ordaz-Rosado D
Int J Pharm; 2009 Jun; 375(1-2):75-83. PubMed ID: 19393305
[TBL] [Abstract][Full Text] [Related]
12. Optimization of 90 Y-antiCD20 preparation for radioimmunotherapy.
Gholipour N; Vakili A; Radfar E; Jalilian AR; Bahrami-Samani A; Shirvani-Arani S; Ghannadi-Maragheh M
J Cancer Res Ther; 2013; 9(2):199-204. PubMed ID: 23771358
[TBL] [Abstract][Full Text] [Related]
13. A novel engineered anti-CD20 tracer enables early time PET imaging in a humanized transgenic mouse model of B-cell non-Hodgkins lymphoma.
Natarajan A; Hackel BJ; Gambhir SS
Clin Cancer Res; 2013 Dec; 19(24):6820-9. PubMed ID: 24097872
[TBL] [Abstract][Full Text] [Related]
14. Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci.
Broekema M; van Eerd JJ; Oyen WJ; Corstens FH; Liskamp RM; Boerman OC; Harris TD
J Med Chem; 2005 Oct; 48(20):6442-53. PubMed ID: 16190770
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, characterization and biodistribution of novel amine thiophene ⁹⁹mTc labeled complex.
Javed M; Khan I; Mobeen S; Dar UK; Hyder SW
Pak J Pharm Sci; 2012 Apr; 25(2):381-7. PubMed ID: 22459466
[TBL] [Abstract][Full Text] [Related]
16. Technetium-99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma.
Camacho X; Machado CL; García MF; Gambini JP; Banchero A; Fernández M; Oddone N; Bertolini Zanatta D; Rosal C; Buchpiguel CA; Chammas R; Riva E; Cabral P
Oncology; 2017; 92(4):229-242. PubMed ID: 28196364
[TBL] [Abstract][Full Text] [Related]
17. Synthesis,
Wang J; Yang W; Xue J; Zhang Y; Liu Y
J Labelled Comp Radiopharm; 2017 Dec; 60(14):659-665. PubMed ID: 29023951
[TBL] [Abstract][Full Text] [Related]
18. Preparation and bioevaluation of (99m)Tc-HYNIC-annexin B1 as a novel radioligand for apoptosis imaging.
Luo QY; Wang F; Zhang ZY; Zhang Y; Lu HK; Sun SH; Zhu RS
Apoptosis; 2008 Apr; 13(4):600-8. PubMed ID: 18307043
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeling and preliminary biological evaluation of a (99m)Tc(CO)(3) labeled 3,3'-(benzylidene)-bis-(1H-indole-2-carbohydrazide) derivative as a potential SPECT tracer for in vivo visualization of necrosis.
Prinsen K; Jin L; Vunckx K; De Saint-Hubert M; Zhou L; Cleynhens J; Nuyts J; Bormans G; Ni Y; Verbruggen A
Bioorg Med Chem Lett; 2011 Jan; 21(1):502-5. PubMed ID: 21075631
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of ⁹⁹mTc(CO)₃(His-CB) as a tumor imaging agent.
Wang J; Yang J; Duan X; Zhang Y; Yang W; Liu Y
Bioorg Med Chem Lett; 2012 Dec; 22(24):7406-9. PubMed ID: 23140886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
